<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="editorial"><?properties open_access?><!-- Original-type: ed--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10638997</article-id><article-id pub-id-type="pmc">2363186</article-id><article-id pub-id-type="pii">6690907</article-id><article-id pub-id-type="doi">10.1054/bjoc.1999.0907</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Survival in renal cell carcinoma: a randomized evaluation of tamoxifen vs interleukin-2, &#x003b1;-interferon (leucocyte) and tamoxifen</article-title></title-group><pub-date pub-type="epub"><day>08</day><month>12</month><year>1999</year></pub-date><pub-date pub-type="ppub"><month>01</month><year>2000</year></pub-date><volume>82</volume><issue>1</issue><fpage seq="a">246</fpage><lpage>246</lpage><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions></article-meta></front></article>


